Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05302908 · ClinicalTrials.gov registry record · NA

COVID-19 Testing and Vaccination Among Spanish Speakers

A NA study of COVID-19 and Vaccinations, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
274
Enrollment target
1
Study location

NCT05302908: Completed NA study of COVID-19 and Vaccinations, sponsored by Wake Forest University Health Sciences.

NCT05302908 is a NA study of COVID-19 and Vaccinations that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 274 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05302908, a NA study of COVID-19 and Vaccinations, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
274 participants
Enrollment target
1
Study location

Study Summary

Latinx communities are disproportionately affected by the COVID-19 pandemic, with Spanish-speaking Latinx communities carrying even heavier burdens of infection, hospitalization, and mortality. Major barriers to COVID-19 testing and vaccination exist, and a profound need remains to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing and vaccination within Latinx communities. Our community-academic partnership proposes a rigorous mixed-methods, community-based participatory research study to better understand the SEBI of COVID-19 testing and vaccination and to refine and test a novel and culturally congruent intervention that integrates two evidenced-based strategies - peer navigation and mHealth - to increase COVID-19 testing and vaccination within Spanish-speaking Latinx communities.

Primary Outcome

Number of Subjects Ever Tested

Conditions Studied

Interventions

  • BEHAVIORAL NuestraSaludSegura

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2023-02-09
Est. Completion 2024-11-30
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT05302908 record still lists

NCT05302908 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which NuestraSaludSegura is the first listed.

NCT05302908 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05302908 about?

NCT05302908 is a clinical study titled "COVID-19 Testing and Vaccination Among Spanish Speakers". Latinx communities are disproportionately affected by the COVID-19 pandemic, with Spanish-speaking Latinx communities carrying even heavier burdens of infection, hospitalization, and mortality. Major barriers to COVID-19 testing and vaccination exist, and a profound need remains to understand and ad...

What is the current status of trial NCT05302908?

This trial is currently completed. It is a NA study. The enrollment target is 274 participants. The study started on 2023-02-09. Estimated completion is 2024-11-30.

What conditions does trial NCT05302908 study?

This clinical trial studies the following conditions: COVID-19, Vaccinations.

What interventions are being tested in trial NCT05302908?

The interventions under investigation include: NuestraSaludSegura (BEHAVIORAL).

Who is sponsoring clinical trial NCT05302908?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05302908 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05302908's enrollment target sits among peer trials

274 147th of 298 higher than 151 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04573504 · 274 participants · Phase 4

    Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

  • NCT05289557 · 274 participants · Phase 3

    The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

  • NCT05952583 · 274 participants

    Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

  • NCT06173401 · 274 participants · Phase 3

    Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05302908, the US trial registry maintained by the National Library of Medicine. NCT05302908 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.